Nipro Corporation (Osaka, Japan) has signed a definitive agreement to acquire Infraredx, Inc. (Burlington, Massachusetts).
Nipro Corporation (Osaka, Japan) has signed a definitive agreement to acquire Infraredx, Inc. (Burlington, Massachusetts). Nipro Corporation has broad holdings in pharmaceuticals and medical devices. Infraredx is an intravascular imaging company working to advance the diagnosis and management of coronary artery disease globally.
The agreement combines Nipro’s global cardiovascular portfolio with Infraredx’s industry expertise in near infrared spectroscopy and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States, and continue Infraredx’s mission to provide cardiologists with advanced imaging tools designed to predict heart attacks and prevent them.
“We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease,” Jason Bottiglieri, president and CEO of Infraredx, said in a statement.
The acquisition, which is subject to certain conditions, is expected to close in October 2015.
An Interview with AES Mid-Career Award Recipient Jason Dwyer
July 25th 2024Jason Dwyer of the University of Rhode Island has been named the recipient of the American Electrophoresis Society’s Mid-Career Award, which honors exceptional contributions to the field of electrophoresis, microfluidics, and related areas by an individual who is currently in the middle of their career.
Glucose's Impact on Brain Cancer Cells Unveiled Through Raman Imaging
July 25th 2024Researchers have used Raman spectroscopy and chemometric methods to reveal how glucose affects normal and cancerous brain cell metabolism. Their findings highlight specific biomarkers that can distinguish metabolic changes, potentially aiding in cancer research and treatment.